Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.

MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.

Food may reduce the absorption and blood levels of eltrombopag. In addition, minerals such as aluminum, calcium, iron, magnesium, and zinc can also interfere with eltrombopag absorption into the bloodstream, which may make the medication less effective in treating your condition. You should take eltrombopag on an empty stomach one hour before or two hours after a meal. Eltrombopag should also be taken at least 2 hours before or 4 hours after products like antacids, mineral supplements, dairy products, and fortified juices. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.